Wedbush Securities Inc. Has $1.19 Million Stock Holdings in Zoetis Inc (NYSE:ZTS)

Wedbush Securities Inc. grew its holdings in Zoetis Inc (NYSE:ZTS) by 1.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,492 shares of the company’s stock after purchasing an additional 191 shares during the quarter. Wedbush Securities Inc.’s holdings in Zoetis were worth $1,191,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Huntington National Bank lifted its stake in shares of Zoetis by 3.0% in the 2nd quarter. Huntington National Bank now owns 2,975 shares of the company’s stock valued at $338,000 after purchasing an additional 87 shares during the period. Rehmann Capital Advisory Group lifted its stake in shares of Zoetis by 4.0% in the 1st quarter. Rehmann Capital Advisory Group now owns 2,550 shares of the company’s stock valued at $257,000 after purchasing an additional 97 shares during the period. Abbrea Capital LLC lifted its stake in shares of Zoetis by 2.9% in the 1st quarter. Abbrea Capital LLC now owns 3,530 shares of the company’s stock valued at $355,000 after purchasing an additional 100 shares during the period. Ipswich Investment Management Co. Inc. lifted its stake in shares of Zoetis by 4.2% in the 2nd quarter. Ipswich Investment Management Co. Inc. now owns 2,484 shares of the company’s stock valued at $282,000 after purchasing an additional 100 shares during the period. Finally, Eukles Asset Management lifted its stake in shares of Zoetis by 0.7% in the 1st quarter. Eukles Asset Management now owns 14,241 shares of the company’s stock valued at $1,434,000 after purchasing an additional 101 shares during the period. 90.08% of the stock is currently owned by institutional investors.

Zoetis stock traded down $0.61 during midday trading on Wednesday, reaching $123.35. The stock had a trading volume of 442,145 shares, compared to its average volume of 2,156,563. Zoetis Inc has a 12 month low of $78.90 and a 12 month high of $125.88. The company has a market cap of $59.87 billion, a P/E ratio of 39.41, a P/E/G ratio of 3.16 and a beta of 0.92. The business has a fifty day moving average price of $115.93. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.08. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.51 billion. During the same period in the previous year, the company posted $0.77 EPS. The firm’s revenue was up 9.3% compared to the same quarter last year. On average, equities analysts expect that Zoetis Inc will post 3.57 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be issued a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio is currently 21.09%.

A number of brokerages have recently issued reports on ZTS. Bank of America downgraded Zoetis from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $111.00 to $120.00 in a research note on Monday, July 1st. They noted that the move was a valuation call. Craig Hallum boosted their target price on Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. BMO Capital Markets boosted their target price on Zoetis from $101.00 to $105.00 and gave the company a “market perform” rating in a research report on Thursday, May 9th. Gabelli lowered Zoetis from a “buy” rating to a “hold” rating and set a $108.00 target price for the company. in a research report on Thursday, May 2nd. They noted that the move was a valuation call. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 target price (up from $116.00) on shares of Zoetis in a research report on Wednesday, June 12th. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $115.13.

In other Zoetis news, insider Clinton A. Jr. Lewis sold 6,123 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $113.09, for a total transaction of $692,450.07. Following the completion of the sale, the insider now directly owns 46,812 shares of the company’s stock, valued at approximately $5,293,969.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,900 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $110.58, for a total value of $210,102.00. Following the sale, the director now directly owns 2,816 shares of the company’s stock, valued at $311,393.28. The disclosure for this sale can be found here. Insiders have sold a total of 29,537 shares of company stock valued at $3,184,955 over the last three months. Corporate insiders own 0.29% of the company’s stock.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: Are we seeing the beginning of a new bubble?

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit